Therefore, the impact of a congenital FXI deficiency on bleeding tendencies and treatment of individuals with thrombotic disorders with inhibitors of FXIa or FXIIa should be further investigated to better understand the impact on hemostasis and the potential bleeding risk associated with such interventions. This evidence concerns the gene F11 and hyperinsulinemic hypoglycemia, familial, 4.